The antiserum was produced against synthesized peptide derived from human TIE2 around the phosphorylation site of Tyr1102. AA range:1068-1117

Phospho-Tie-2 (Y1102) Polyclonal Antibody detects endogenous levels of Tie-2 protein only when phosphorylated at Y1102.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):KTyVN

TEK

Angiopoietin-1 receptor

TEK ;
TIE2 ;
VMCM ;
VMCM1 ;
Angiopoietin-1 receptor ;
Endothelial tyrosine kinase ;
Tunica interna endothelial cell kinase ;
Tyrosine kinase with Ig and EGF homology domains-2 ;
Tyrosine-protein kinase receptor TEK ;
Tyrosine-protein kinase receptor

This gene encodes a receptor that belongs to the protein tyrosine kinase Tie2 family. The encoded protein possesses a unique extracellular region that contains two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin type III repeats. The ligand angiopoietin-1 binds to this receptor and mediates a signaling pathway that functions in embryonic vascular development. Mutations in this gene are associated with inherited venous malformations of the skin and mucous membranes. Alternative splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Feb 2014],

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Disease:Defects in TEK are a cause of dominantly inherited venous malformations (VMCM) [MIM:600195]; an error of vascular morphogenesis characterized by dilated, serpiginous channels.,Function:This protein is a protein tyrosine-kinase transmembrane receptor for angiopoietin 1. It may constitute the earliest mammalian endothelial cell lineage marker. Probably regulates endothelial cell proliferation, differentiation and guides the proper patterning of endothelial cells during blood vessel formation.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. Tie subfamily.,similarity:Contains 1 protein kinase domain.,similarity:Contains 2 Ig-like C2-type (immunoglobulin-like) domains.,similarity:Contains 3 EGF-like domains.,similarity:Contains 3 fibronectin type-III domains.,tissue specificity:Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney.,

Cell membrane ; Single-pass type I membrane protein. Cell junction . Cell junction, focal adhesion . Cytoplasm, cytoskeleton. Secreted . Recruited to cell-cell contacts in quiescent endothelial cells (PubMed:18425120, PubMed:18425119). Colocalizes with the actin cytoskeleton and at actin stress fibers during cell spreading. Recruited to the lower surface of migrating cells, especially the rear end of the cell. Proteolytic processing gives rise to a soluble extracellular domain that is secreted (PubMed:11806244). .

Detected in umbilical vein endothelial cells. Proteolytic processing gives rise to a soluble extracellular domain that is detected in blood plasma (at protein level). Predominantly expressed in endothelial cells and their progenitors, the angioblasts. Has been directly found in placenta and lung, with a lower level in umbilical vein endothelial cells, brain and kidney.

>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>HIF-1 signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Rheumatoid arthritis